Table 7.

Computer-aided ADME study of the prepared derivatives.

Compound	AlogP98 a	PSA_2D b	Solubility c	Solubility Level d	Absorption Level e	CYP2D6 f	CYP2D6 Probability g
5a	3.684	43.616	−4.830	2	0	0	0.316
5b	4.171	43.616	−5.324	2	0	1	0.554
5c	2.938	70.156	−4.307	2	0	0	0.376
5d	4.349	43.616	−5.560	2	0	0	0.376
5e	3.890	43.616	−5.158	2	0	0	0.336
5f	3.890	43.616	−5.152	2	0	0	0.376
5g	4.095	43.616	−5.478	2	0	0	0.326
5h	4.433	43.616	−5.636	2	0	0	0.287
5i	3.579	86.440	−5.034	2	0	0	0.257
5j	3.442	64.432	−4.355	2	0	0	0.326
5k	3.442	64.432	−4.363	2	0	0	0.336
5l	3.442	64.432	−4.366	2	0	0	0.386
5m	3.668	52.547	−4.911	2	0	0	0.376
5n	3.668	52.547	−4.887	2	0	0	0.396
5o	3.426	73.362	−4.486	2	0	0	0.425
5p	3.652	61.477	−4.959	2	0	0	0.306
5q	3.652	61.477	−4.949	2	0	1	0.524
5r	3.453	61.477	−5.112	2	0	0	0.346
5s	3.635	70.407	−5.013	2	0	1	0.554
5t	4.017	52.547	−5.102	2	0	0	0.366
5u	3.287	28.624	−4.870	2	0	0	0.306
5v	3.080	56.171	−4.348	2	0	0	0.099
5w	3.410	43.616	−4.643	2	0	0	0.425

^a Lipophilicity descriptor; ^b Polar surface area; ^c Solubility parameter. (0–−2 = optimal, −2–−4 = good, −4–−6 = low, −6–−8 = very low); ^d Solubility level. (0 = extremely low, 1 = very low but possible, 2 = low, 3 = good, 4 = optimal); ^e Absorption level. (0 = good, 1 = moderate, 2 = low, 3 = very low); ^f CYP2D inhibition. (0 = non inhibitor, 1 = inhibitor); ^g CYP2D6 Probability: 0–0.5 = non inhibitor; 0.5–1 = inhibitor.